November, 2004 Slide 1 FDA PROMOTIONAL RULES The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Arthur N. Levine.

Slides:



Advertisements
Similar presentations
An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Advertisements

@ PMCQ October 14, Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
DAVID R. HOFFMAN Assistant U. S. Attorney 615 Chestnut Street Suite 1250 Philadelphia, PA Phone: (215) Fax: (215)
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
25-1 Chapter 44 Consumer Protection and Product Safety.
RAC Study Group Chapter 16
May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.
FCA LIABILITY FOR OFF-LABEL MARKETING THOMAS M. GREENE Greene & Hoffman November 8, 2005 Serostim Update.
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.
August, 2005 Slide 1 MANAGING RISKS OF OFF-LABEL PROMOTION AND CONTINUING MEDICAL EDUCATION The FDA Regulatory and Compliance Symposium Annenberg Hall.
© 2010 Dorsey & Whitney LLP Social Media Friday, September 17, 2010 The Committee on Finance & Information Technology (CFIT)
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Recent False Claims Developments Robert J. Sherry K&L Gates May 2009.
The Regulatory Authority for Off-Label Promotion
Off Label Promotion of Medical Devices presented by Bradley Merrill Thompson Epstein Becker & Green P.C. June 21, 2006.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
20__ Fredrikson & Byron P.A A Practical Path -- Does the First Amendment Matter? Presented by Bob Klepinski
Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Overview of FDA's Regulatory Compliance Agenda Daniel Meron, Esq. General Counsel Department of Health and Human Services August 22, 2007.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.
FleetBoston Financial HIPAA Privacy Compliance Agnes Bundy Scanlan Managing Director and Chief Privacy Officer FleetBoston Financial.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
FDA Regulation of Prescription Drug Promotion Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
7 th Annual National Pharmaceutical Congress November 9, 2006 Off-Label Promotion: Risks, Controls and Assessment John T. Bentivoglio Co-Leader FDA/Healthcare.
Conducting a Clinical Compliance Risk Assessment in the Pharmaceutical Industry Presentation to: The 2 nd Annual Medical Research Summit March 25, 2002.
Mass Media Law 18 th Edition Don Pember Clay Calvert Chapter 15 Regulation of Advertising McGraw-Hill/Irwin © 2013 McGraw-Hill Companies. All Rights Reserved.
Prof. Moustafa M. Mohamed Vice dean Dr. Safa Ahmed El-askary Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation.
Investigational Devices and Humanitarian Use Devices June 2007.
1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
Enforcement Litigation and Compliance Washington, DC December 9- 10, 2015 Food: Industry Self Regulation Hal Hodes, Attorney, National Advertising Division.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
California’s New Compliance Law Kelly N. Reeves
National Pharma Audioconference: Lessons of BMS' $515 Million Settlement for Off-label Promotion, Kickbacks and Drug Pricing Kathleen Meriwether Principal,
Special Concerns Relating To Promotional Labeling And Advertising For Medical Devices.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
Promotion of Prescription Drugs and Biologics Thomas O. Henteleff Kleinfeld, Kaplan and Becker LLP Company logo here.
FDA Regulation of Pharmaceutical Marketing Tom Casola Executive Director Commercial Operations Merck & Co., Inc.
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Reprints.
FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.
Presenting Truthful Information to Doctors Aaron S. Kesselheim, M.D., J.D. Brigham and Women ’ s Hospital Harvard School of Public Health Boston, Massachusetts.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Lessons Learned from Federal Prosecutions Michael K. Loucks First Assistant U.S. Attorney District of Massachusetts.
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
Washington Legal Foundation Advocate for Freedom and Justice ® WLF Balancing the Public's Right to Know With the Government's Obligation to Protect Patients.
Chapter 4 The Legal and Regulatory Environment of Health Care.
Prescription Drug Advertising
How to Put Together an IDE Application
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
Trends: Two Months & Four Settlements That Have Changed Our World
Complying with FDA/OIG Rules
Analysis of the Proposed Sunshine Rule: Legal Considerations
Off-label Promotion: Managing the Regulatory Risks
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Generic Medical Device Company (“MDC”)
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
CLINICAL TRIAL REGISTRIES
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Pharmaceutical Compliance Congress November 15, 2004
2006 PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS NOVEMBER 9,2006
Compliance in the New Environment
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

November, 2004 Slide 1 FDA PROMOTIONAL RULES The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Arthur N. Levine Arnold & Porter LLP November, 2004

Slide 2 n A drug manufacturer may not promote a drug for a use that FDA has not approved n Dissemination of information about an unapproved use does not always run afoul of FDA’s rules --Responses to unsolicited physician questions --Medical education and “scientific exchange” --Peer reviewed, independent journal articles n But disseminating company-produced off-label claims to physicians or advertising off-label uses to consumers will be viewed by FDA as violative n Dissemination of information about an unapproved use by or on behalf of a manufacturer can have consequences beyond FDA regulatory action

November, 2004 Slide 3 The Basic FDA Rules for Rx Drug Promotion n FDA approved labeling (the PI) is the regulatory point of reference n Promotional materials must be consistent with the FDA-approved labeling n Claims may not be false or misleading or lacking in fair balance

November, 2004 Slide 4 How FDA Assesses Promotional Materials n Submission at time of first use (2253 Form) n Submission of launch materials (optional) n FDA oversight and monitoring --labeling --mailers (Dr. Healthcare provider letters) --brochures --reprints --exhibits --websites --sales aids --press materials --SEC submissions (mandatory disclosure of material information?) --advertising (journals, magazines, TV ads) --non-print evidence of intended use

November, 2004 Slide 5 What is FDA Looking For? n Unsubstantiated comparative or superiority claims n Claims that are misleading by omission --Failure to reveal important risk or safety information --Minimizing warning information --Failure to reveal limitations on use n Implied claims of broader indications, broader conditions of use, larger patient population n Drug-of-choice claims n Misleading DTC ads n Company compensation schedules and marketing plans

November, 2004 Slide 6 Where Does the First Amendment Come In? n Drug promotional material is commercial speech n Regulation of commercial speech based on four questions --Does the speech concern a lawful activity and is the speech false or inherently misleading? --Is the government’s interest in regulating (restricting or limiting) the speech substantial? --Does the regulation of the speech directly advance the government’s interest? --Is the regulation more extensive than necessary to serve that interest? (“If the government can achieve its interests in a manner that does not restrict speech, or that restricts less speech, the government must do so.” Thompson v. Western States)

November, 2004 Slide 7 FDA’s First Amendment Interests n FDA has a substantial interest in preserving the integrity of the drug review process by requiring manufacturers to demonstrate the safety and effectiveness of claims in order to get them approved (on-label) n Restricting off-label use directly advances FDA’s interest in promoting on-label use of drugs n Are FDA restrictions more extensive than necessary? --It depends

November, 2004 Slide 8 Where the First Amendment Balance Stands n As a result of court decisions, it appears that companies can disseminate copies of peer-reviewed journal articles to doctors, or disseminate portions of bona fide, independently published textbooks to doctors --If the company also disseminates the PI, discloses that the use discussed in article/text is not approved, and discloses the manufacturer’s support for the work that is reported in the article/text n Companies can sponsor CME where off-label uses will be discussed

November, 2004 Slide 9 Where the First Amendment Balance Stands [cont’d] n Doctors can lawfully prescribe a drug for an off-label use n A claim may be inherently misleading when addressed to non- physicians n Truthful, non-misleading information is not fully protected --U.S. v. Caputo, D.N.J off-label prosecution permitting defendants to engage in all forms of truthful --Non-misleading off-label promotion would frustrate FDA’s ability to evaluate the effectiveness of off-label uses --Manufacturers would seek FDA approval of only those uses which could be approved easily and inexpensively --Court is “unable to identify a less burdensome alternative that would advance the government’s substantial interest. Thus, the FDA prohibitions are not more extensive than necessary.”

November, 2004 Slide 10 n FDA notice of March 2000 regarding off-label use n FDA enforcement on case-by-case basis (DDMAC) n October 2003 Compliance Policy Guide (Marketed Unapproved Drugs) n Regulatory focus on misleading statements

November, 2004 Slide 11 New Challenges of Off-Label Promotion n Causing the submission of a false claim under the False Claims Act (Franklin v. Parke-Davis) --Submission for payment of off-label prescription (a not- covered outpatient drug) is a material misrepresentation to obtain a government benefit --Off-label prescription submitted for reimbursement by Medicaid can be a false claim under the FCA --Where the manufacturer’s knowing conduct “causes” the submission --“Causing” may be based on reasonably foreseeable submissions --Truthful off-label promotion and improper financial incentives (such as kickbacks) are enough

November, 2004 Slide 12 False Claims Act Exposure n Violations of FCA -- $5,000-$11,000 per false claim n Violations of FDCA n Related risks --Exclusion from healthcare reimbursement programs --Corporate Integrity Agreements --State unfair trade practice laws n “Implied Certification” n Neurontin settlement

November, 2004 Slide 13 New Players -- Who Sets Federal Healthcare Policy? n Whistleblowers (Franklin) --Qui tam suits --Improper/constructive discharge claims n State Attorneys General --State consumer protection and unfair competition statutes --Actions by one or more state AGs --AGs interested in off-label promotion, DTC advertising, fair balance, comparative/superiority claims --Compliance with FDA-approved labeling may not be enough --FDA review of promotional materials may not be enough n State legislatures -- new California law requiring compliance with PhRMA Code and OIG Compliance Program

November, 2004 Slide 14 New Players -- Who Sets Federal Healthcare Policy? [cont’d] n HHS OIG (FCA enforcement) n Department of Justice (Anti-Kickback enforcement) n FDA/DDMAC cooperation with the SEC, CMS, and FTC n Product liability lawyers Competitors -- deceptive advertising/unfair competition litigation n Shareholder liability suits -- Board misconduct/stock price manipulation n Insurance carriers --Excluded coverage for foreseeable adverse events --Off-label promotion/foreseeable events not in labeling may negate learned intermediary defense

November, 2004 Slide 15 New Off-Label Issue n Clinical trial databases --GSK settlement with AG Spitzer --Forest Labs settlement with AG Spitzer --Lilly/Merck clinical trial databases --PhRMA database (Oct. 2004) -- publicly available, free access database --Results of Phase III and IV clinical tests completed since October Published articles and unpublished study summaries --Sponsor’s name --Name of drug/studied indications

November, 2004 Slide 16 New Off-Label Issue [cont’d] --Link to FDA approved labeling --Bibliography of published studies --Database searchable by drug name, indication studied, study name, sponsor --Ongoing clinical studies --Cancer Heart disease/stroke Neurological disease n What will this mean for companies and their sales representatives?

November, 2004 Slide 17 Conducting An Off-Label Assessment n Identify key products with potential or known off-label uses n Review policies and procedures that address off-label uses n Evaluate adequacy of existing training programs on off-label compliance issues n Review relevant complaints to internal hotline or other internal reporting mechanisms n Review recent FDA regulatory actions, whistleblower suits, judicial decisions, settlements n Review complaints from competitors n Assess effectiveness of compliance and audit programs

November, 2004 Slide 18 Special Areas for Review n Off-label information -- who, when, how n Promotional materials n Instructions to and restrictions on sales representatives n Role of medical liaisons n Funding for medical education n Marketing plans n Compensation of sales representatives n Interactions with physicians n News releases n Websites